Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15720487 | 0.70 | LMNA (0.42) | LMNACA12CA1CA2CA3 | |
| SCHEMBL12156956 | 0.70 | LMNA (0.61) | LMNACA12CA1CA2CA3 | |
| SCHEMBL569047 | 0.70 | JMJD6 (0.32) | CA12CA1CA2CA9 | |
| SCHEMBL14889017 | 0.69 | MAPT (0.37) | CA12CA1CA2CA9 | |
| SCHEMBL9986639 | 0.68 | KDM4E (0.38) | LMNACA12CA1CA2CA9 | |
| SCHEMBL27653216 | 0.67 | SYK (0.32) | — | |
| SCHEMBL14834787 | 0.65 | LMNA (0.55) | LMNACA12CA1CA2CA3 | |
| SCHEMBL4555640 | 0.65 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL14163977 | 0.64 | LMNA (0.54) | LMNACA12CA1CA2CA3 | |
| SCHEMBL8201977 | 0.64 | LMNA (0.59) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293363-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2024-09-05 | — | — | US | disclosed |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| US-20220218665-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2022-07-14 | — | — | US | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210244709-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2021-08-12 | — | — | US | disclosed |
| EP-3827820-A1 | BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3260118-B1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10806717-B2 | Methods and compositions for improving cognitive function | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-20150094352-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-04-02 | — | — | US | disclosed |
| US-20140206667-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | THE JOHNS HOPKINS UNIVERSITY | 2014-07-24 | — | — | US | disclosed |
| CN-103476255-A | Methods and compositions for improving cognitive function | UNIV JOHNS HOPKINS | 2013-12-25 | — | — | CN | disclosed |
| US-8604075-B2 | Methods and compositions for improving cognitive function | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-12-10 | — | — | US | disclosed |
| US-20120214859-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2012-08-23 | — | — | US | disclosed |
| US-20120046336-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| US-20100099735-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2010-04-22 | — | — | US | disclosed |
| US-7244747-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-07-17 | — | — | US | disclosed |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806717-B2 | Methods and compositions for improving cognitive function | GRIN2A, CHRNA2, SYNGR2 | LMNA 1805/4885CA12 302/4885CA1 322/4885 |
| US-20120046336-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | LMNA 2747/4885CA12 1722/4885CA1 967/4885 |
| US-20150094352-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | LMNA 2747/4885CA12 1722/4885CA1 967/4885 |
| US-20210244709-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | LMNA 1805/4885CA12 302/4885CA1 322/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | LMNA 1020/4885CA12 483/4885CA1 828/4885 |
| US-20100099735-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | LMNA 2747/4885CA12 1722/4885CA1 967/4885 |
| US-20140206667-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | RAB2A, SYNGR2, GRIN2A | LMNA 2092/4885CA12 1001/4885CA1 882/4885 |
| US-20240293363-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | LMNA 2747/4885CA12 1722/4885CA1 967/4885 |
| US-20120214859-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, GRIN2D, SLC18A2 | LMNA 1386/4885CA12 186/4885CA1 176/4885 |
| US-20220218665-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | LMNA 2747/4885CA12 1722/4885CA1 967/4885 |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | LMNA 1805/4885CA12 302/4885CA1 322/4885 |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | LMNA 763/4885CA12 825/4885CA1 350/4885 |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | LMNA 763/4885CA12 825/4885CA1 350/4885 |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2D, GRIN2A, SLC18A2 | LMNA 1152/4885CA12 123/4885CA1 109/4885 |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | CYP3A4, PPIP5K2, CYP2C19 | LMNA 2706/4885CA12 4434/4885CA1 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.